Author/Authors :
EISSA, SANAA Ain Shams University - Faculty of Medicine - Medical Biochemistry Department, Oncology Diagnostic Unit, Egypt , SWELLAM, MENHA National Research Center - Department of Biochemistry, Genetic Engineering and Biotechnology Division, Egypt , ABDEL MALAK, CAMILIA Damietta University - Faculty of Science - Biochemistry Division, Egypt , FAHIM, MOHAMED NOSHI Damietta University - Faculty of Science - Biochemistry Division, Egypt , FAKHR EL-DEEN, RASHA RASHEED Misr University for Science and Technology (MUST University) - Faculty of Pharmacy - Department of Biochemistry, Egypt , MOUSTAFA, MOHAMED F. Misr University for Science and Technology (MUST University) - Faculty of Pharmacy - Department of Biochemistry, Egypt , ABDEL FATTAH, ABEER IBRAHIM ill-ilzhar University - Faculty of Pharmacy (Girls) - Department of Biochemistry, Egypt , ESMAT, MOHAMED Ain Shams University - Faculty of Medicine - Department of Urology, Egypt
Abstract :
Purpose: Fas/CD95, a membrane-bound type I protein, plays a key role in induction of apoptosis and in tumorogenesis. Authors adapted and evaluated measurement of urinary sFas using enzyme-linked immunosorbent assay and compared the results with voided urine cytology. Material and Methods: Voided urine samples were provided from 203 individuals (120 bladder cancer [112 bilharzial]; 43 benign urologic disorders [20 bilharzial dysplastic lesions]; 40 healthy volunteers). Urine sediment was used for cytology and the supernatant for estimation of sFas by ELISA. Results: Receiver operating characteristic curve (ROC) curve was used to determine the best cutoff value for urinary sFas. Positivity rates and mean rank levels for sFas showed significant difference among the three investigated groups (p 0.0001), and was related to bilharzial infection, pathological type, clinical stages and histological grades (p 0.01). The sensitivity of sFas for early detection of bladder cancer especially those with superficial and low grades tumors was superior to urine cytology, moreover, sensitivity of urine cytology was improved when combined with sFas. Conclusion: Urinary sFas may be used as a novel noninvasive diagnostic marker for bilharzial bladder cancer patients. Further multicentric studies are warranted to corroborate these findings and to establish an optimal sFas cut-point.
